Clinical trials are currently evaluating the safety and efficacy of several FcRn‐targeting compounds (e.g., efgartigimod (ARGX-113) and SYNT001 (ALXN1830)) in pemphigus (96–98). This evidence concerns the gene FCGRT and pemphigus.